X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NVD-003 is an autologous therapy derived from adipose stem cells, which reverses severe bone deterioration and to achieve accelerated ossification, is being investigated as a single treatment to save limbs and restore mobility in patients with CPT.
Lead Product(s): NVD-003
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: NVD-003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
NVD-003, an autologous tissue engineered product generated from the patients’ own adipose stem cells, was applied in nine patients with bone non-union of the lower limb who had previously undergone several surgical procedures.
Lead Product(s): NVD-003
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: NVD-003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
NVD-X3 is an allogeneic therapeutic that can provide accelerated, durable bone union in spinal fusion procedures and non-healing fractures, and NVD-003 is an autologous bone engraftment product designed to provide a single treatment cure for critical size bone defects.
Lead Product(s): NVD-X3
Therapeutic Area: Musculoskeletal Product Name: NVD-X3
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Science Ventures
Deal Size: $88.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 03, 2022
Details:
NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform. Study met its primary endpoint. NVD-001 showed a favorable safety profile over a two-year observation period.
Lead Product(s): NVD-001
Therapeutic Area: Neurology Product Name: NVD-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform.
Lead Product(s): NVD-001
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: NVD-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
NVD-003 is a novel autologous cell-based osteogenic (bone healing) product that has been generated from Novadip’s proprietary tissue regeneration platform. Made from adipose stem cells, NVD-003 has a 3-dimensional structure and works by promoting bone formation.
Lead Product(s): NVD-003
Therapeutic Area: Rare Diseases and Disorders Product Name: NVD-003
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
